197 related articles for article (PubMed ID: 19694940)
1. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function.
Flood VH; Friedman KD; Gill JC; Morateck PA; Wren JS; Scott JP; Montgomery RR
J Thromb Haemost; 2009 Nov; 7(11):1832-9. PubMed ID: 19694940
[TBL] [Abstract][Full Text] [Related]
2. A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients.
Vangenechten I; Mayger K; Smejkal P; Zapletal O; Michiels JJ; Moore GW; Gadisseur A
J Thromb Haemost; 2018 Jul; 16(7):1268-1277. PubMed ID: 29742318
[TBL] [Abstract][Full Text] [Related]
3. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.
Flood VH; Gill JC; Morateck PA; Christopherson PA; Friedman KD; Haberichter SL; Hoffmann RG; Montgomery RR
Blood; 2011 Feb; 117(6):e67-74. PubMed ID: 21148813
[TBL] [Abstract][Full Text] [Related]
4. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.
Stufano F; Baronciani L; Pagliari MT; Franchi F; Cozzi G; Garcia-Oya I; Bucciarelli P; Boscarino M; Peyvandi F
J Thromb Haemost; 2015 Oct; 13(10):1806-14. PubMed ID: 26206100
[TBL] [Abstract][Full Text] [Related]
6. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
[TBL] [Abstract][Full Text] [Related]
7. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
[TBL] [Abstract][Full Text] [Related]
8. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.
Stufano F; Lawrie AS; La Marca S; Berbenni C; Baronciani L; Peyvandi F
Haemophilia; 2014 Jan; 20(1):147-53. PubMed ID: 24028703
[TBL] [Abstract][Full Text] [Related]
9. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay.
Riddell AF; Jenkins PV; Nitu-Whalley IC; McCraw AH; Lee CA; Brown SA
Br J Haematol; 2002 Jan; 116(1):187-92. PubMed ID: 11841416
[TBL] [Abstract][Full Text] [Related]
10. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
11. Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity?
Casonato A; Pontara E; Bertomoro A; Sartorello F; Cattini MG; Girolami A
Br J Haematol; 2001 Mar; 112(3):578-83. PubMed ID: 11260057
[TBL] [Abstract][Full Text] [Related]
12. A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.
Stepanian A; Ribba AS; Lavergne JM; Fressinaud E; Juhan-Vague I; Mazurier C; Girma JP; Meyer D
Br J Haematol; 2003 Feb; 120(4):643-51. PubMed ID: 12588351
[TBL] [Abstract][Full Text] [Related]
13. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
14. The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor.
Ribba AN; Hilbert L; Lavergne JM; Fressinaud E; Boyer-Neumann C; Ternisien C; Juhan-Vague I; Goudemand J; Girma J; Mazurier C; Meyer D
Blood; 2001 Feb; 97(4):952-9. PubMed ID: 11159522
[TBL] [Abstract][Full Text] [Related]
15. Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.
Larsen DM; Haberichter SL; Gill JC; Shapiro AD; Flood VH
Haemophilia; 2013 Jul; 19(4):590-4. PubMed ID: 23496210
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin.
Graf L; Moffat KA; Carlino SA; Chan AK; Iorio A; Giulivi A; Hayward CP
Int J Lab Hematol; 2014 Jun; 36(3):341-51. PubMed ID: 24750681
[TBL] [Abstract][Full Text] [Related]
17. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
[TBL] [Abstract][Full Text] [Related]
18. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
[TBL] [Abstract][Full Text] [Related]
19. Comparison of von Willebrand factor (VWF) activity levels determined by HemosIL AcuStar assay and HemosIL LIA assay with ristocetin cofactor assay by aggregometry.
Sagheer S; Rodgers S; Yacoub O; Dauer R; Mcrae S; Duncan E
Haemophilia; 2016 May; 22(3):e200-7. PubMed ID: 27076201
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]